Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | MET | P08581 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 6/20 | 0.58 |
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.50 |
| ▸ | PLK1 | P53350 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27700676 | 0.84 | ALDH1A1 (0.63) | ALDH1A1SMN1; SMN2LMNAMETNPC1 | |
| SCHEMBL21104475 | 0.83 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2LMNAMETNPC1 | |
| SCHEMBL6985862 | 0.80 | ALDH1A1 (0.78) | ALDH1A1SMN1; SMN2LMNANPC1POLB | |
| SCHEMBL6978649 | 0.80 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2LMNANPC1POLB | |
| SCHEMBL6984890 | 0.79 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2LMNANPC1POLB | |
| SCHEMBL6978659 | 0.79 | BRAF (0.57) | ALDH1A1SMN1; SMN2LMNAMETNPC1 | |
| SCHEMBL17442655 | 0.78 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2LMNAMETNPC1 | |
| SCHEMBL6979083 | 0.78 | SMN1; SMN2 (0.74) | ALDH1A1SMN1; SMN2LMNAMAPTMEN1 | |
| SCHEMBL6089373 | 0.78 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2LMNANPC1POLB | |
| SCHEMBL3155590 | 0.78 | NPC1 (0.62) | ALDH1A1SMN1; SMN2LMNANPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687493-B2 | Product, method and intermediates for the preparation of azetidine derivatives | AVENTIS PHARMA SA (FR) | 2010-03-30 | — | — | US | claimed |
| US-20070270463-A1 | NOVEL PRODUCT, METHOD AND INTERMEDIATES FOR THE PREPARATION OF AZETIDINE DERIVATIVES | SANOFI-AVENTIS (FR) | 2007-11-22 | — | — | US | claimed |
| EP-1805167-A2 | NOVEL PRODUCT, METHOD AND INTERMEDIATES FOR THE PREPARATION OF AZETIDINE DERIVATIVES | Aventis Pharma S.A. (FR) | 2007-07-11 | — | — | EP | claimed |
| WO-2006040465-A2 | NOVEL PRODUCT, METHOD AND INTERMEDIATES FOR THE PREPARATION OF AZETIDINE DERIVATIVES | AVENTIS PHARMA S.A. (FR) | 2006-04-20 | — | — | WO | claimed |
| EP-1263722-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, NOVEL AZETIDINE DERIVATIVES AND PREPARATION THEREOF | AVENTIS PHARMA SA (FR) | 2010-08-25 | — | — | EP | disclosed |
| US-7687493-B2 | Product, method and intermediates for the preparation of azetidine derivatives | AVENTIS PHARMA SA (FR) | 2010-03-30 | — | — | US | disclosed |
| US-20070270463-A1 | NOVEL PRODUCT, METHOD AND INTERMEDIATES FOR THE PREPARATION OF AZETIDINE DERIVATIVES | SANOFI-AVENTIS (FR) | 2007-11-22 | — | — | US | disclosed |
| EP-1805167-A2 | NOVEL PRODUCT, METHOD AND INTERMEDIATES FOR THE PREPARATION OF AZETIDINE DERIVATIVES | Aventis Pharma S.A. (FR) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006040465-A2 | NOVEL PRODUCT, METHOD AND INTERMEDIATES FOR THE PREPARATION OF AZETIDINE DERIVATIVES | AVENTIS PHARMA S.A. (FR) | 2006-04-20 | — | — | WO | disclosed |
| CN-1418192-A | Pharmaceutical compositions containing azetidine derivatives novel azetidine derivatives and preparation thereof | AVENTIS PHARMA SA (FR) | 2003-05-14 | — | — | CN | disclosed |
| EP-1263722-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, NOVEL AZETIDINE DERIVATIVES AND PREPARATION THEREOF | Aventis Pharma S.A. (FR) | 2002-12-11 | — | — | EP | disclosed |
| US-6355631-B1 | TREATMENT OF PSYCHOSIS AND SCHIZOPHRENIA | AVENTIS PHARMA S.A. (FR) | 2002-03-12 | — | — | US | disclosed |
| WO-2001064634-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, NOVEL AZETIDINE DERIVATIVES AND PREPARATION THEREOF | AVENTIS PHARMA S.A. (FR) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270463-A1 | NOVEL PRODUCT, METHOD AND INTERMEDIATES FOR THE PREPARATION OF AZETIDINE DERIVATIVES | QDPR, AZI2, NISCH | ALDH1A1 1155/4885SMN1; SMN2 3211/4885LMNA 3957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.